About InVivoSIM anti-human IL-4Rα (CD124) (Dupilumab Biosimilar) This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Dupilumab making it ideal for research use. This Dupilumab biosimilar reacts with human IL-4Rα. IL-4Rα also known as CD124, associates with either the common γ-chain (CD132) to form type 1 IL-4R which only binds IL-4 or with IL-13Rα1 to form type II IL-4R which can bind IL-4 or IL-13. IL-4Rα is expressed on various cell types, including T helper type 2 (Th2) cells, mast cells, basophils, eosinophils, macrophages, dendritic cells, and endothelial cells. The expression of IL-4Rα on these different cell types allows for a variety of cellular responses to IL-4 and IL-13, including regulation of immune cell differentiation, activation, proliferation, and survival. Additionally, IL-4 and IL-13 signaling through IL-4Rα can promote tissue repair and remodeling, as well as contribute to the pathogenesis of various allergic and inflammatory diseases. Dupilumab binds IL-4Rα and inhibits signaling of both IL-4 and IL-13. It has shown efficacy across multiple diseases with underlying type 2 signatures and is used for treatment of asthma, atopic dermatitis, and chronic sinusitis with nasal polyposis. InVivoSIM anti-human IL-4Rα (CD124) (Dupilumab Biosimilar) Specifications IsotypeHuman IgG4, κ Recommended Isotype Control(s)RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenHuman IL-4Rα Reported ApplicationsFunctional assays FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein A Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
